Solskin
Halozyme Therapeutics (NYSE:HAL) intends to finance its 2B euro ($2.1B) proposed acquisition of Germany’s Evotec (EVO) in cash, Bloomberg reported Sunday, quoting Chief Executive Helen Torley.
“We feel confident in being able to fund this as a fully cash deal,” Torley